The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias

British Journal of Pharmacology
A N DohadwallaE M Vaughan Williams


1. (+)-propranolol and (+/-)-propranolol are comparable in their potency as a local anaesthetic on the intact and desheathed frog sciatic nerve.2. (+/-)-propranolol is much more potent than (+)-propranolol as a beta-receptor blocking agent and also more effective than the latter in protecting guinea-pigs against ouabain-induced ventricular fibrillation.3. In isolated rabbit atria (-)-, (+)- and (+/-)-propranolol, and I.C.I. 50172, which has hardly any local anaesthetic activity, greatly reduce the rate of rise of the intracellularly recorded action potential at concentrations which have no significant effect on electrical threshold, contractions, spontaneous frequency, maximum driving frequency, repolarization time or conduction velocity.


May 1, 1967·British Journal of Pharmacology and Chemotherapy·F R CiofaloJ Roberts
Jan 1, 1966·British Journal of Pharmacology and Chemotherapy·B G Benfey, D R Varma
Feb 10, 1967·Annals of the New York Academy of Sciences·B F Hoffman, D H Singer
Jan 1, 1968·British Journal of Pharmacology and Chemotherapy·D Dunlop, R G Shanks
Sep 1, 1967·European Journal of Pharmacology·C Raper, A Jowett
Sep 1, 1966·The American Journal of Cardiology·E M Williams
May 20, 1956·The Journal of General Physiology·O F HUTTER, W TRAUTWEIN
Sep 1, 1958·British Journal of Pharmacology and Chemotherapy·E M Vaughan Williams
Nov 16, 1963·British Medical Journal·J P STOCK, N DALE
Mar 7, 1964·British Medical Journal·J P PAYNE, R M SENFIELD
Dec 1, 1963·British Journal of Pharmacology and Chemotherapy·A SEKIYA, E M VAUGHANWILLIAMS
Feb 1, 1965·The Journal of Pharmacology and Experimental Therapeutics·P SOMANI, B K LUM
Apr 1, 1965·British Journal of Pharmacology and Chemotherapy·A MORALES AGUILERA, E M VAUGHANWILLIAMS
Mar 1, 1962·The Journal of Physiology·L SZEKERES, E M Williams


Jan 1, 1990·European Journal of Clinical Pharmacology·K Endresen, J P Amlie
Jun 18, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·F Ebner, M Reiter
Apr 5, 1974·Naunyn-Schmiedeberg's Archives of Pharmacology·D M TempleM Makinose
May 1, 1971·European Journal of Pharmacology·P SOMANI, A R Laddu
Jul 1, 1971·European Journal of Pharmacology·B Spilker, S Shevde
Jul 1, 1971·European Journal of Pharmacology·J R BoissierS Larno
Nov 1, 1972·European Journal of Pharmacology·G J Kelliher, J Roberts
Nov 1, 1973·European Journal of Pharmacology·N CaginB Levitt
Dec 1, 1973·European Journal of Pharmacology·G J Kelliher, T M Glenn
Feb 1, 1974·European Journal of Pharmacology·E M Vaughan Williams, P Polster
Nov 1, 1975·European Journal of Pharmacology·B N SinghR M Whitlock
Sep 1, 1976·European Journal of Pharmacology·N Goupil, J Lenfant
Feb 7, 1977·European Journal of Pharmacology·J Inui, H Imamura
Sep 24, 1982·European Journal of Pharmacology·E M Williams, T J Campbell
Feb 18, 1992·European Journal of Pharmacology·M BoucherP Duchêne-Marullaz
May 19, 1993·European Journal of Pharmacology·A N HoqueY Abiko
Jan 1, 1982·Pharmacology & Therapeutics·R S Bexton, A J Camm
Jan 1, 1975·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·E M Vaughan Williams
Feb 13, 2001·European Journal of Pharmacology·T HorioM Itoh
Aug 1, 1970·British Journal of Pharmacology·B N Singh, E M Vaughan Williams
Jan 1, 1972·British Journal of Pharmacology·B N Singh, E M Vaughan Williams
Nov 1, 1972·British Journal of Pharmacology·G J KelliherJ Roberts
Aug 1, 1973·British Journal of Pharmacology·E E Bagwell, E M Williams
Feb 1, 1977·British Journal of Pharmacology·R J Marshall, J R Parratt
Jan 1, 1972·Acta Pharmacologica Et Toxicologica·H Refsum, K Landmark
Apr 1, 1996·The Journal of Pharmacy and Pharmacology·M J HagertyK A Kane
Feb 27, 1971·British Medical Journal·D J ColtartD G Shand
Feb 17, 1978·Brain Research·E TribolletD W Lincoln
Jan 1, 1974·Progress in Cardiovascular Diseases·D E Jewitt, B N Singh
Nov 1, 1976·Progress in Cardiovascular Diseases·M E ConollyC T Dollery
Sep 1, 1986·British Journal of Pharmacology·M BoucherJ L Moundanga
Feb 1, 1983·British Journal of Pharmacology·H Downes, S M Taylor
Mar 1, 1984·The American Journal of Cardiology·B TrimarcoM Condorelli
Jul 1, 1984·Medicinal Research Reviews·M Simonyi
Jan 13, 2006·British Journal of Pharmacology·M J A Walker
Apr 1, 1973·The Journal of Pharmacy and Pharmacology·M K Lavender, M W Parkes
Feb 1, 1970·British Journal of Pharmacology·I L Natoff, B Reiff

Related Concepts

Nerve Impulses
Neural Therapy of Huneke
Cardiac Arrhythmia
Cavia porcellus
Right Atrial Structure
Pulse Rate

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.